Table 4

Change in Average MIT From Baseline to Month 12 by Lipid Category According to American Heart Association Criteria Guidelines

Everolimus 1.5 mg (n = 88)MMF (n = 101)
Lipid ParameterCategory (mg/dl)Change (mm)Subgroup NumberChange (mm)Subgroup Number
Total cholesterolDesirable<2000.020420.06270
Borderline High200–2390.025240.07024
High≥2400.035220.1497
LDL cholesterolOptimal<1000.017350.03942
Near or above optimal100–1290.019280.08647
Borderline High130–1590.051160.1008
High≥1600.01560.1504
TriglyceridesNormal<1500.017220.05048
Borderline High150–1990.028290.07623
High200–4990.027370.09830
HDL cholesterolLow<400.01660.10116
Normal40–590.035330.06464
Optimal≥600.020490.06421
Total cholesterol/HDL cholesterolNormal≤6.3 (male)
≤5.5 (female)
0.026800.05586
High>5.5 (male)
>5.5 (female)
0.01780.15914
Statin use at Month 12, %98.997.0

p = 0.222, 0.481, 0.181, and 0.472 for the interactions of change in average maximal intimal thickness (MIT) with total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides, respectively. p Value for the interaction with total cholesterol/HDL cholesterol was not calculated because only a few patients had high level of total cholesterol/HDL cholesterol.

HDL = high-density lipoprotein; LDL = low-density lipoprotein; MMF = mycophenolate mofetil.